JP2020533354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533354A5 JP2020533354A5 JP2020514916A JP2020514916A JP2020533354A5 JP 2020533354 A5 JP2020533354 A5 JP 2020533354A5 JP 2020514916 A JP2020514916 A JP 2020514916A JP 2020514916 A JP2020514916 A JP 2020514916A JP 2020533354 A5 JP2020533354 A5 JP 2020533354A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- composition according
- hcmv
- antigen
- full
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023198785A JP2024026160A (ja) | 2017-09-13 | 2023-11-24 | ヒトサイトメガロウイルス免疫原性組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306179.7 | 2017-09-13 | ||
| EP17306179 | 2017-09-13 | ||
| PCT/EP2018/074369 WO2019052975A1 (en) | 2017-09-13 | 2018-09-11 | IMMUNOGENIC COMPOSITION AGAINST HUMAN CYTOMEGALOVIRUS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198785A Division JP2024026160A (ja) | 2017-09-13 | 2023-11-24 | ヒトサイトメガロウイルス免疫原性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533354A JP2020533354A (ja) | 2020-11-19 |
| JP2020533354A5 true JP2020533354A5 (enExample) | 2021-09-30 |
| JP7770767B2 JP7770767B2 (ja) | 2025-11-17 |
Family
ID=60782111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514916A Active JP7770767B2 (ja) | 2017-09-13 | 2018-09-11 | ヒトサイトメガロウイルス免疫原性組成物 |
| JP2023198785A Pending JP2024026160A (ja) | 2017-09-13 | 2023-11-24 | ヒトサイトメガロウイルス免疫原性組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198785A Pending JP2024026160A (ja) | 2017-09-13 | 2023-11-24 | ヒトサイトメガロウイルス免疫原性組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11524069B2 (enExample) |
| EP (1) | EP3681534A1 (enExample) |
| JP (2) | JP7770767B2 (enExample) |
| KR (2) | KR20200051778A (enExample) |
| CN (1) | CN111344009A (enExample) |
| AU (1) | AU2018331874B2 (enExample) |
| BR (1) | BR112020004747A2 (enExample) |
| IL (1) | IL273120B2 (enExample) |
| MX (1) | MX2020002810A (enExample) |
| SG (1) | SG11202002174SA (enExample) |
| WO (1) | WO2019052975A1 (enExample) |
| ZA (1) | ZA202001561B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200051778A (ko) | 2017-09-13 | 2020-05-13 | 사노피 파스퇴르 | 인간 시토메갈로바이러스 면역원성 조성물 |
| US12290560B2 (en) * | 2018-12-10 | 2025-05-06 | Km Biologics Co., Ltd. | Vaccine for preventing or treating congenital infection with cytomegalovirus |
| TWI871709B (zh) | 2020-06-21 | 2025-02-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| KR20230097028A (ko) * | 2020-10-28 | 2023-06-30 | 사노피 파스퇴르 | Tlr4 효현제를 함유하는 리포좀, 이의 제조 및 용도 |
| CN116617383A (zh) * | 2022-02-14 | 2023-08-22 | 华中师范大学 | 一种基于铝佐剂的联合佐剂系统、疫苗制剂及其制备方法与应用 |
| WO2024218752A1 (en) * | 2023-04-21 | 2024-10-24 | Instar Technologies A.S. | Pharmaceutical composition for vaccination against cytomegalovirus infections |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
| US6100064A (en) | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5547834A (en) | 1988-01-29 | 1996-08-20 | Chiron Corporation | Recombinant CMV neutralizing proteins |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| KR920701453A (ko) | 1989-03-17 | 1992-08-11 | 미리엄 디. 멕코나헤이 | 유전자발현의 외부조절 |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US20020102562A1 (en) | 1995-05-24 | 2002-08-01 | Pasteur Merieux Serums Et Vaccines S.A. | Recombinant CMV neutralizing proteins |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6835721B2 (en) | 1999-02-01 | 2004-12-28 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| EP2263687B1 (en) | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| US7704510B2 (en) * | 2006-06-07 | 2010-04-27 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| CA2699756A1 (en) * | 2007-09-21 | 2009-03-26 | Sanofi Pasteur | Vaccine composition for the prevention of cmv infection |
| CN105944095B (zh) | 2008-03-05 | 2021-04-02 | 赛诺菲巴斯德有限公司 | 一种使含佐剂的疫苗组合物稳定的方法 |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| MA34802B1 (fr) | 2010-10-15 | 2014-01-02 | Glaxosmithkline Biolog Sa | Nouvel antigène |
| NZ616304A (en) * | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| US11058762B2 (en) * | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| AU2013286093B2 (en) | 2012-07-06 | 2018-01-04 | Novartis Ag | Complexes of cytomegalovirus proteins |
| CA2879577C (en) | 2012-07-27 | 2021-08-03 | City Of Hope | An mva vaccine for delivery of a ul128 complex and preventing cmv infection |
| EP3269388A1 (en) * | 2012-10-30 | 2018-01-17 | Pfizer Inc. | Recombinant particle based vaccines against human cytomegalovirus infection |
| EP3134117A1 (en) * | 2014-04-23 | 2017-03-01 | Institute for Research in Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| MX2016014660A (es) * | 2014-05-08 | 2017-02-28 | Pfizer | Medios y metodos para el tratamiento de cmv. |
| EP3031822A1 (en) | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| EP3347045A4 (en) * | 2015-09-10 | 2019-08-28 | City of Hope | MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR |
| EP3364981A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| KR102724939B1 (ko) * | 2016-06-17 | 2024-11-01 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 선형 또는 분지형 폴리아크릴산 폴리머 아쥬반트를 포함하는 신규한 면역원성 제형 |
| KR20200051778A (ko) | 2017-09-13 | 2020-05-13 | 사노피 파스퇴르 | 인간 시토메갈로바이러스 면역원성 조성물 |
-
2018
- 2018-09-11 KR KR1020207010481A patent/KR20200051778A/ko not_active Ceased
- 2018-09-11 US US16/646,894 patent/US11524069B2/en active Active
- 2018-09-11 JP JP2020514916A patent/JP7770767B2/ja active Active
- 2018-09-11 AU AU2018331874A patent/AU2018331874B2/en active Active
- 2018-09-11 EP EP18765127.8A patent/EP3681534A1/en active Pending
- 2018-09-11 KR KR1020247040905A patent/KR20250006307A/ko active Pending
- 2018-09-11 WO PCT/EP2018/074369 patent/WO2019052975A1/en not_active Ceased
- 2018-09-11 BR BR112020004747-3A patent/BR112020004747A2/pt not_active Application Discontinuation
- 2018-09-11 SG SG11202002174SA patent/SG11202002174SA/en unknown
- 2018-09-11 MX MX2020002810A patent/MX2020002810A/es unknown
- 2018-09-11 IL IL273120A patent/IL273120B2/en unknown
- 2018-09-11 CN CN201880072392.9A patent/CN111344009A/zh active Pending
-
2020
- 2020-03-12 ZA ZA2020/01561A patent/ZA202001561B/en unknown
- 2020-10-15 US US17/071,817 patent/US11207403B2/en active Active
-
2022
- 2022-12-08 US US18/077,713 patent/US20230277655A1/en not_active Abandoned
-
2023
- 2023-11-24 JP JP2023198785A patent/JP2024026160A/ja active Pending
-
2025
- 2025-01-14 US US19/020,003 patent/US20250228933A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases | |
| Huang et al. | Research progress on emulsion vaccine adjuvants | |
| Petkar et al. | An overview of nanocarrier-based adjuvants for vaccine delivery | |
| Lin et al. | Calcium phosphate nanoparticles as a new generation vaccine adjuvant | |
| Cui et al. | Vaccine adjuvants: current status, research and development, licensing, and future opportunities | |
| Shah et al. | Overview of vaccine adjuvants: introduction, history, and current status | |
| HRP20160816T1 (hr) | Upotreba virusa influence i emulzije ulja u vodi kao adjuvansa radi poticanja t-stanica cd4 i/ili poboljšanog odgovora memorijskih b-stanica | |
| O’Hagan et al. | New generation adjuvants–from empiricism to rational design | |
| JP7053106B2 (ja) | リピドａ模倣体、調製方法、及びその使用 | |
| JP2014532620A5 (enExample) | ||
| Bramwell et al. | Particulate delivery systems for vaccines | |
| ES2647902T3 (es) | Método de administración de vacunas | |
| Dowling et al. | Pediatric vaccine adjuvants: Components of the modern vaccinologist's toolbox | |
| JP2019518739A5 (enExample) | ||
| JP2013053146A5 (enExample) | ||
| HRP20130023T1 (hr) | Cjepivo koje sadrži emulziju ulje u vodi kao adjuvans | |
| Martiñón et al. | Chemical and immunological characteristics of aluminum‐based, oil‐water emulsion, and bacterial‐origin adjuvants | |
| Zeng et al. | In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives | |
| JP2009514839A5 (enExample) | ||
| Rambe et al. | Safety and mechanism of action of licensed vaccine adjuvants | |
| Kallerup et al. | Influence of trehalose 6, 6′-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes | |
| Blom et al. | Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition | |
| Gupta et al. | Adjuvants in micro‐to nanoscale: current state and future direction | |
| Burakova et al. | Food‐Grade Saponin Extract as an Emulsifier and Immunostimulant in Emulsion‐Based Subunit Vaccine for Pigs | |
| Bioley et al. | Long-term persistence of immunity induced by OVA-coupled gas-filled microbubble vaccination partially protects mice against infection by OVA-expressing Listeria |